Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ernexa Therapeutics (ERNA) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Ernexa Therapeutics (ERNA) over the last 15 years, with Q3 2025 value amounting to 2.1%.

  • Ernexa Therapeutics' Return on Capital Employed fell 10000.0% to 2.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.1%, marking a year-over-year decrease of 10000.0%. This contributed to the annual value of 0.65% for FY2024, which is 800.0% up from last year.
  • Latest data reveals that Ernexa Therapeutics reported Return on Capital Employed of 2.1% as of Q3 2025, which was down 10000.0% from 2.78% recorded in Q2 2025.
  • In the past 5 years, Ernexa Therapeutics' Return on Capital Employed ranged from a high of 2.39% in Q1 2025 and a low of 6.98% during Q3 2022
  • Over the past 5 years, Ernexa Therapeutics' median Return on Capital Employed value was 2.07% (recorded in 2021), while the average stood at 1.99%.
  • Per our database at Business Quant, Ernexa Therapeutics' Return on Capital Employed tumbled by -49100bps in 2022 and then surged by 64700bps in 2023.
  • Quarter analysis of 5 years shows Ernexa Therapeutics' Return on Capital Employed stood at 2.07% in 2021, then fell by -15bps to 2.38% in 2022, then surged by 80bps to 0.48% in 2023, then plummeted by -820bps to 4.41% in 2024, then surged by 52bps to 2.1% in 2025.
  • Its Return on Capital Employed stands at 2.1% for Q3 2025, versus 2.78% for Q2 2025 and 2.39% for Q1 2025.